# Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

> **NCT02503423** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Taiho Oncology, Inc.** · enrollment: 253 (actual)

## Conditions studied

- Solid Tumors
- Lymphoma

## Interventions

- **DRUG:** ASTX660

## Key facts

- **NCT ID:** NCT02503423
- **Lead sponsor:** Taiho Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-07-14
- **Primary completion:** 2022-10
- **Final completion:** 2027-12
- **Target enrollment:** 253 (ACTUAL)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02503423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02503423, "Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02503423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*